03:28 PM EST - Cipher Pharmaceuticals Inc. : announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica™, Cipher's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. Absorica is expected to be launched in the U.S. in Q4 2012. Cipher Pharmaceuticals Inc.
shares T.DND are trading up $0.94 at $2.19.
